<DOC>
	<DOC>NCT02675803</DOC>
	<brief_summary>This study will investigate the safety and tolerability of VAY736 administered as single ascending doses of intravenous infusion, subcutaneous injection and repeated subcutaneous injections in rheumatoid arthritis patients.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>This study will have three sequential parts which will investigate the safety and tolerability of VAY736 administered as single ascending doses of intravenous infusion (Part 1), single ascending doses of subcutaneous injection (Part 2), and repeated subcutaneous injections of fixed doses (Part 3), respectively, in rheumatoid arthritis patients. Part 1 is double blind, placebo controlled, with 11 cohorts. Part 2 is open-label study with 2 dosing cohorts. Part 3 is open-label study with 1 fixed-dose cohort.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Active disease despite methotrexate treatment 5 to 20 mg/week for Parts 1 and 2; methotrexate treatment 5 to 20 mg/week for Part 3 Fulfilled 2010 American College of Rheumatolody (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis for Part 1 and Part 2. For Part 3, fulfilled 2010 American College of Rheumatolody (ACR)/)/European League Against Rheumatism (EULAR) classification criteria or/and 1987 American College of Rheumatolody (ACR) classification criteria for rheumatoid arthritis; Methotrexate ≥ 16 weeks, stable dose ≥ 8 weeks Previous treatment with a B celldepleting biologic agent. Autoimmune disease other than RA except concurrent Sjogren's syndrome Adult juvenile rheumatoid arthritis ARA functional class IV disease of ACR Revised Steinbrocker Classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>